Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$65.95
-1.3%
$57.39
$35.95
$69.48
$5.31B0.551.20 million shs1.36 million shs
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$77.50
+2.3%
$62.55
$33.31
$93.25
$4.71B2.21.69 million shs1.24 million shs
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$34.67
-0.6%
$32.18
$22.61
$46.48
$5.53B1.971.80 million shs1.44 million shs
Zymeworks Inc. stock logo
ZYME
Zymeworks
$18.40
-0.8%
$15.76
$9.03
$19.50
$1.38B1.51544,658 shs446,971 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
-1.30%-0.42%+8.74%+38.46%+79.70%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
+2.34%-10.92%+30.87%+39.69%+64.93%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
-0.57%+2.70%+8.21%-8.55%+41.51%
Zymeworks Inc. stock logo
ZYME
Zymeworks
-0.81%+1.88%+15.94%+29.12%+36.30%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$65.95
-1.3%
$57.39
$35.95
$69.48
$5.31B0.551.20 million shs1.36 million shs
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$77.50
+2.3%
$62.55
$33.31
$93.25
$4.71B2.21.69 million shs1.24 million shs
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$34.67
-0.6%
$32.18
$22.61
$46.48
$5.53B1.971.80 million shs1.44 million shs
Zymeworks Inc. stock logo
ZYME
Zymeworks
$18.40
-0.8%
$15.76
$9.03
$19.50
$1.38B1.51544,658 shs446,971 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
-1.30%-0.42%+8.74%+38.46%+79.70%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
+2.34%-10.92%+30.87%+39.69%+64.93%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
-0.57%+2.70%+8.21%-8.55%+41.51%
Zymeworks Inc. stock logo
ZYME
Zymeworks
-0.81%+1.88%+15.94%+29.12%+36.30%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
2.53
Moderate Buy$69.004.62% Upside
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
2.83
Moderate Buy$74.00-4.52% Downside
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
2.67
Moderate Buy$49.0041.33% Upside
Zymeworks Inc. stock logo
ZYME
Zymeworks
3.00
Buy$24.7534.51% Upside

Current Analyst Ratings Breakdown

Latest ZYME, PTGX, TGTX, and PTCT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/17/2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$72.00 ➝ $96.00
10/16/2025
Zymeworks Inc. stock logo
ZYME
Zymeworks
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$20.00 ➝ $23.00
10/14/2025
Zymeworks Inc. stock logo
ZYME
Zymeworks
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetNeutralBuy$13.00 ➝ $26.00
10/13/2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
10/13/2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
Johnson Rice
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$112.00
10/10/2025
Zymeworks Inc. stock logo
ZYME
Zymeworks
B. Riley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$30.00
10/8/2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C-)
10/8/2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D+)
10/8/2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$80.00
10/8/2025
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C-)
10/7/2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
Johnson Rice
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$74.00
(Data available from 10/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$806.78M6.49N/AN/A($14.24) per share-4.63
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$434.43M11.10$4.62 per share16.76$11.33 per share6.84
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$329M16.72$0.12 per share290.67$1.43 per share24.24
Zymeworks Inc. stock logo
ZYME
Zymeworks
$122.87M11.26N/AN/A$6.63 per share2.78
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
-$363.30M$6.979.46N/AN/A35.65%-106.31%30.61%11/6/2025 (Estimated)
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$275.19M$0.70110.72N/AN/A24.88%8.12%7.41%11/6/2025 (Estimated)
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$23.38M$0.3793.7034.67N/A13.31%26.05%9.58%11/3/2025 (Estimated)
Zymeworks Inc. stock logo
ZYME
Zymeworks
-$118.67M-$0.97N/AN/AN/A-182.75%-23.00%-18.04%10/30/2025 (Estimated)

Latest ZYME, PTGX, TGTX, and PTCT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2025Q3 2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
-$1.11N/AN/AN/A$177.42 millionN/A
11/6/2025Q3 2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
-$0.59N/AN/AN/A$5.41 millionN/A
11/3/2025Q3 2025
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$0.24N/AN/AN/A$152.12 millionN/A
10/30/2025N/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
-$0.28N/AN/AN/A$33.69 millionN/A
8/7/2025Q2 2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
-$1.07-$0.83+$0.24-$0.83$173.01 million$178.88 million
8/7/2025N/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
-$0.52$0.03+$0.55N/A$17.18 million$48.73 million
8/6/2025Q2 2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
-$0.53-$0.55-$0.02-$0.55$8.32 million$5.55 million
8/4/2025Q2 2025
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$0.32$0.17-$0.15$0.17$147.76 million$141.15 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/AN/AN/AN/AN/A
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
N/AN/AN/AN/AN/A
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
N/AN/AN/AN/AN/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/A
3.62
3.57
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
N/A
16.97
16.97
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
0.89
3.86
2.96
Zymeworks Inc. stock logo
ZYME
Zymeworks
N/A
4.10
4.10

Institutional Ownership

CompanyInstitutional Ownership
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/A
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
98.63%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
58.58%
Zymeworks Inc. stock logo
ZYME
Zymeworks
92.89%

Insider Ownership

CompanyInsider Ownership
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
5.50%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
4.90%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
10.64%
Zymeworks Inc. stock logo
ZYME
Zymeworks
1.92%
CompanyEmployeesShares OutstandingFree FloatOptionable
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
1,41079.44 million75.07 millionOptionable
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
12062.21 million59.16 millionOptionable
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
290158.67 million141.78 millionOptionable
Zymeworks Inc. stock logo
ZYME
Zymeworks
46075.17 million67.56 millionOptionable

Recent News About These Companies

What is HC Wainwright's Forecast for Zymeworks Q3 Earnings?
HC Wainwright & Co. Upgrades Zymeworks (ZYME)
Zymeworks (NYSE:ZYME) Shares Gap Up - Here's Why
Equities Analysts Set Expectations for Zymeworks Q3 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTC Therapeutics stock logo

PTC Therapeutics NASDAQ:PTCT

$65.95 -0.87 (-1.30%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$65.08 -0.87 (-1.32%)
As of 10/17/2025 05:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Protagonist Therapeutics stock logo

Protagonist Therapeutics NASDAQ:PTGX

$77.50 +1.77 (+2.34%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$77.50 0.00 (0.00%)
As of 10/17/2025 06:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

TG Therapeutics stock logo

TG Therapeutics NASDAQ:TGTX

$34.67 -0.20 (-0.57%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$34.62 -0.05 (-0.13%)
As of 10/17/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

Zymeworks stock logo

Zymeworks NYSE:ZYME

$18.40 -0.15 (-0.81%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$18.65 +0.25 (+1.36%)
As of 10/17/2025 06:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.